Seeking Alpha
 

Inhibitex, Inc. (INHX)

- NASDAQ
INHX is defunct.
  • Jan. 27, 2012, 8:56 AM
    Idenix Pharmaceuticals (IDIX) -9.6% after Stifel Nicolaus downgrades shares to Sell from Hold at Stifel Nicolaus, which believes the "significant difference" in potency existing between IDIX's hepatitis C drug and those made by Pharmasset (VRUS) and Inhibitex (INHX) has important implications on how remaining "potential consolidators" strategically view the companies.
    | Comment!
  • Jan. 24, 2012, 10:36 AM
    Following a common theme of Hepatitis C-related stocks running together, Achillion Pharmaceuticals (ACHN +12.1%) rallies strongly after Israel-based BioLineRX announces a major development deal. Other Hep-C players to watch: INHX, IDIX, VRTX.
    | Comment!
  • Jan. 11, 2012, 10:49 AM
    Fitch maintains Bristol-Myers Squibb's (BMY) debt rating at A+ and its outlook at Negative following the drug company's deal to buy Inhibitex (INHX) for $2.5B. While Bristol has enough cash to pay for Inhibitex, the latter won't provide immediate relief to an expected fall in Bristol's revenues because of the expiration of patents.
    | Comment!
  • Jan. 9, 2012, 12:59 PM
    Other Hepatitis C drug-developers' shares rally on the back of Bristol-Myers (BMY -1.1%) plans to buy Inhibitex (INHX +141%): Idenix Pharmaceuticals (IDIX +34%), Achillion Pharmaceuticals (ACHN +16%) and Vertex Pharmaceuticals (VRTX +4%).
    | Comment!
  • Jan. 9, 2012, 5:53 AM
    Bristol-Myers Squibb (BMY) said over the weekend that it has agreed to buy Inhibitex (INHX)  for $2.5B as it looks to boost its pipeline ahead of the loss of patent protection for its blood thinner Plavix. The $26/share bid is over double Inhibitex's $9.87 close on Friday despite its main drug, for hepatitis C, only being in mid-stage trials. (PR)
    | 1 Comment
  • Jan. 6, 2012, 3:33 PM
    Shares of Inhibitex (INHX +2.3%) tack on a gain, helped along with a note from Noble Financial's Nathan Cali to clients saying he believes the firm's INX-189 drug increases the chances of a "lucrative" partnership deal or merger in the future.
    | Comment!
  • Jan. 4, 2012, 6:03 PM
    Inhibitex (INHX -6.4%) had an interesting day. Shares fell as much as 16% in early trading, apparently due to cautious comments from BofA's Rachel McMinn, who thinks there could be considerable downside if a safety check for the company's INX-189 hepatitis drug turns up any issues. However, shares pared the majority of their losses after other analysts came to Inhibitex's defense.
    | Comment!
  • Dec. 30, 2011, 8:05 PM
    Top five Dow gainers of 2011: MCD +31%, IBM +27%, PFE +24%, HD +20%, KFT +20%. Top S&P gainers: COG +103%, EP +92%, ISRG +81%, MA +69%, BIIB +65%. Top Nasdaq gainers: VRUS +469%, EGAN +412%, SIMO +392%, INHX +308%, TSTF +276%.
    | 1 Comment
  • Dec. 16, 2011, 9:59 AM
    Following news that Pharmasset (VRUS -3.4%) will discontinue Phase 2b trials of its hepatitis drug, other hepatitis-related companies are seeing dramatic share movement. Rallying: VRTX +3.9%, ACHN +1.4%. Declining: INHX -27%, IDIX -13.3%.
    | Comment!
  • Nov. 29, 2011, 9:11 AM
    Inhibitex (INHX) gains 6.5% in premarket trading after reporting positive data from clinical tests of its INX-189 hepatitis C treatment and saying it plans to expand its testing to evaluate the effect of various doses. The company notes it will use the proceeds from a 1.9M common stock offering to help support its INHX-189 development in 2012.
    | Comment!
  • Nov. 29, 2011, 9:00 AM
    Premarket gainers: STX +9%. CEDC +9%. INHX +7%. ONXX +4%. TS +4%. GOLD +4%. RIMM +3%. TCL +3%.
    Losers: TIF -8%. RIG -6%. TLAB -3%.
    | Comment!
  • Nov. 21, 2011, 11:02 AM
    The huge runup in shares of Inhibitex (INHX +32%) following the announcement of the Gilead-Pharmasset deal makes sense to Canaccord Genuity. Analysts with the firm say the premium paid by Gilead (GILD -11.3%) validates the nuc prodrug platform and will "provide a backbone" to the hepatitis C treatment landscape for both INHX and GILD.
    | Comment!
  • Nov. 21, 2011, 9:00 AM
    Premarket gainers: GEDU +96%. VRUS +86%. INHX +30%. CLDX +8%. CTIC +6%. CLWR +6%. DNDN +6%. CBE +5%.
    Losers: GERN -7%. KYG -6%. GILD -6%. RIO -5%. FRO -5%. RDN -4%. LNKD -4%. MT -4%. AIXG -3%. INVN -3%. GMCR -3%. CIM -3%. RIMM -3%. ANR -3%. BCS -3%. JEF -3%. AKS -3%. MPEL -3%. MU -3%. RMBS -3%. BHP -3%. DB -3%. TM -3%. NOK -3%. IHG -3%. BIDU -3%. PCX -3%. VALE -3%.
    | Comment!
  • Nov. 21, 2011, 8:00 AM
    Shares of Hepatitis C treatment providers Inhibitex (INHX) and Vertex Pharmaceuticals (VRTX) show upward momentum following the news of Gilead's (GILD) blockbuster deal to buy Pharmasset (VRUS). Premarket: INHX +31%, VRTX +2%.
    | Comment!
  • Nov. 15, 2011, 10:31 AM
    Canaccord Genuity analyst Randall Stanicky lines up three specialty pharmaceutical stocks with strong catalyst-driven upside potential before year-end: (1) Teva Pharmaceuticals (TEVA -0.3%) on generic Lipitor potential; (2) Inhibitex (INHX -0.1%) ahead of top-line results from INX-189; (3) Raptor (RPTP +0.3%) due to key six-month tolerability data set to be released in Dec.
    | Comment!
  • Nov. 8, 2011, 9:05 AM
    Premarket gainers: MSSR +28%. DYN +20%. YPF +7%. BCRX +9%. NBG +6%. ING +6%. DRYS +6%. SIG +6%. FRO +6%. LYG +5%. RAX +5%. RENN +5%. GTAT +4%. PLCM +4%. NVO +3%. ASML +3%. ATVI +3%. DNDN +3%. AMRN +3%. HFC +3%. JEF +3%. EK +3%.
    Losers: TRGT -55%. AMLN -9%. JRCC -7%. ALLT -7%. FOSL -7%. LGCY -5%. TGI -5%. PXD -4%. ETP -4%. INHX -3%. ALU -3%. URBN -3%. AZN -3%.
    | Comment!
Visit Seeking Alpha's
Company Description
Currently, there's no company description for INHX.
Sector: Healthcare
Industry: Biotechnology
Country: United States